Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.25%
#3 Glidr Glidr +36.87%
#4 CoW Protocol CoW Protocol +35.58%
#5 Humanity Humanity +26.67%
#6 Codatta Codatta +18.76%
#7 Walrus Walrus +18.15%
#8 Enso Enso +18.11%
#9 The Black Bull The Black Bull +14.64%
#10 Collector Crypt Collector Crypt +14.30%
Coin of the day
EXOD EXOD
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Clasificación en acciones #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Precio por acción
$0.117
Última sincronización: 2025-04-04
Capitalización bursátil
$2.45M
Cambio (1 día)
-13.59%
Cambio (1 año)
0.00%
País
US
Comercio Carmell Therapeutics Corporation (CTCX)

Categoría

Healthcare
Ganancias de Carmell Therapeutics Corporation (CTCX)
Ganancias en Jun 2026 TTM: $-6.79M
Secondo gli ultimi rapporti finanziari di Carmell Therapeutics Corporation, gli utili attuali della società sono $-6.79M. Nel 2023, la società ha registrato un utile di $-16.21M, una disminución en comparación con agli utili del 2022, che erano di $-9.05M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Carmell Therapeutics Corporation desde 2021 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-6.79M -36.81%
2024 $-10.75M -33.68%
2023 $-16.21M 79.04%
2022 $-9.05M 2,647.97%
2021 $-329.38K 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -77,766.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -28,821.01%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -44,355.62%
BE